Category Archives: "INforMS"

How multiple sclerosis can be triggered by brain cell death
Multiple sclerosis (MS) may be triggered by the death of brain cells that make the insulation around nerve fibers, a surprising new view [...]
Pregnancy hormone could keep multiple sclerosis at bay
Taking a pregnancy hormone staves off multiple sclerosis relapses, a small clinical trial suggests. The results hint at a potential [...]
Trigeminal neuralgia, type of nerve pain, is an early multiple sclerosis symptom
Trigeminal neuralgia affects the fifth cranial nerve, trigeminal, which is responsible for the sensation in the face involved with biting [...]
Exploring new paths for the treatment of multiple sclerosis
(Edmonton) Research from the University of Alberta's Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the [...]
Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS
Wednesday, October 21, 2015 7:31 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Phase 3 ASCEND study investigating natalizumab in the [...]
EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS
Rockland, Massachusetts, October 12, 2015 – EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today [...]
Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada
Thursday, October 8, 2015 1:00 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, aSanofi company, today announced positive new [...]
Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive [...]
EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation
EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation Four research grants awarded [...]
Results from ZINBRYTA phase 3 DECIDE study presented at ECTRIMS
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last